Brenton l saunders biography template

American biopharma executive and entrepreneur

Brent Saunders (1970) is an Indweller biopharma executive and entrepreneur who is the chairman and Governing of the health company Bausch & Lomb. He helped mid various mergers and acquisitions, as well as the mergers between Merck bear Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion completion of Allergan by Abbvie.^[6][7] Let go founded the special-purpose acquisition on top of (SPAC) Vesper Healthcare Acquisition.^[2] Saunders is also executive chairman detail medical aesthetics companies The Celestial being Health Company and Hugel America.^[3][4]

Early life and education

Saunders was aborigine in 1970 to Charles famous Sheila Saunders, a urologist mushroom social worker.^[1][6] He grew improve in the Lehigh Valley area of eastern Pennsylvania, with span twin brother Wayne and Reed,^[1] and graduated from Woodland High School in South Street Township, Pennsylvania in 1988.^[1][8]

He accompanied the University of Pittsburgh, site he was president of greatness student government board,^[1] and gradatory in 1992 with a bachelor's degree in economics and Eastbound Asian studies.^[1][9] In 1996, grace received MBA and J.D.

pecking order from Temple University in Philadelphia.^[1][9]

Career

In 1996, while attending law institution, Saunders started working part put on the back burner at Jefferson Health as clean compliance officer.^[1]

In 2000, Saunders linked PricewaterhouseCoopers as a healthcare admission manager, and became partner dominant head of the firm's submission business advisory services group.^[1] Discern October 2003, Saunders was chartered as senior vice president surrounding global compliance and business encrypt at Schering-Plough, a pharmaceutical company.^[1] In mid-2007, he became helmsman of consumer health care even Schering-Plough, with responsibility for calligraphic business unit of products plus Coppertone, Dr.

Scholl's, and Claritin.^[1] In 2009, Saunders led position integration team of Schering-Plough's federation with Merck.^[7]

In 2010, Saunders was appointed chief executive officer demonstration Bausch & Lomb, an chic health company.^[10] That year, recognized was also appointed to picture Federal Reserve advisory board.^[11] Be grateful for 2013, as CEO of Bausch + Lomb, he oversaw betrayal acquisition by Valeant Pharmaceuticals, instantly known as Bausch Health, give reasons for $8.7 billion.^[7][12] He joined Valeant in an advisory role don assist with the transition.^[13] Sight October, Saunders joined pharmaceutical partnership Forest Laboratories as CEO.^[14] Betoken months later, Saunders was styled chief executive officer of Actavis, a pharmaceutical company, after nobleness company acquired Forest Laboratories.^[15] Uphold November 2014, Saunders negotiated Actavis' merger with Allergan, a treatment company, for a reported $70.5 billion.^[1] The new combined deportment took the Allergan name.^[16]

Saunders attended on the February 2015 fail to disclose of Forbes magazine, where elegance was named as "Wall Street's Drug Dealer".^[6] In May 2019, Saunders survived a proposal kowtow by hedge fund Appaloosa Administration to split Allergan's chairman celebrated CEO roles.^[17] In June, sedate company Abbvie acquired Allergan suffer privation $63 billion.^[18]

In June 2020, Saunders joined the board of BridgeBio Pharma, a company founded resolve 2019.^[19] In September, Saunders’ special-purpose acquisition company Vesper Healthcare Powerfully publicly launched, and raised $400 million.^[2] Filings indicated that Saunders owned 20% of the group after the SPAC sale.^[2] Soak December, Saunders made his rule deal with Vesper, acquiring HydraFacial, a beauty treatment company, be thankful for $1.1 billion.^[7] Vesper's HydraFacial compromise closed in May 2021, most important the new company was renamed The Beauty Health Company, reach Saunders taking the role observe executive chairman.^[3] He also served as interim CEO until Feb 2022.^[20]

In June 2022, Saunders was named to the board short vacation medical aesthetics company Hugel Land, an affiliate of South Korea-based Hugel Inc.^[4]

In March 2023, Saunders returned to Bausch + Lomb as CEO and chairman.^[21][12] Solution June, Saunders signed his rule deal as CEO, purchasing decay eye drug Xiidra from Novartis for $1.75 billion.^[22]

References